Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
- PMID: 34035566
- PMCID: PMC8117886
- DOI: 10.4103/ijcm.IJCM_439_19
Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
Abstract
Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%-60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine.
Keywords: Booster dose; hepatitis B; vaccine.
Copyright: © 2021 Indian Journal of Community Medicine.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Hepatitis B Vaccine in national immunization schedule: a preventive step in India.Hum Vaccin. 2011 Dec;7(12):1387-8. doi: 10.4161/hv.7.12.17878. Epub 2011 Dec 1. Hum Vaccin. 2011. PMID: 22134433
-
Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China.Sci Rep. 2020 Oct 23;10(1):18155. doi: 10.1038/s41598-020-75338-5. Sci Rep. 2020. PMID: 33097788 Free PMC article.
-
Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India.J Gastroenterol Hepatol. 2008 Nov;23(11):1710-5. doi: 10.1111/j.1440-1746.2008.05483.x. Epub 2008 Aug 28. J Gastroenterol Hepatol. 2008. PMID: 18761556
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
-
BCG vaccination in India and tuberculosis in children: newer facets.Indian J Pediatr. 1994 Sep-Oct;61(5):451-62. doi: 10.1007/BF02751703. Indian J Pediatr. 1994. PMID: 7744445 Review.
Cited by
-
Reducing the infectious diseases burden through "life course approach vaccination" in India-a perspective.AIMS Public Health. 2021 Aug 3;8(3):553-562. doi: 10.3934/publichealth.2021045. eCollection 2021. AIMS Public Health. 2021. PMID: 34395705 Free PMC article.
-
Role of vaccine science diplomacy in low-middle-income countries for eradicating the vaccine-preventable diseases: Targeting the "LAST MILE".J Family Med Prim Care. 2021 Aug;10(8):2739-2744. doi: 10.4103/jfmpc.jfmpc_2253_20. Epub 2021 Aug 27. J Family Med Prim Care. 2021. PMID: 34660398 Free PMC article.
References
-
- de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version) J Hepatol. 2003;39(Suppl 1):S3–25. - PubMed
-
- Hepatitis B. [Last accessed on 2018 Dec 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b .
-
- McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(Suppl 1):3–8. - PubMed
-
- Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350:1118–29. - PubMed
-
- Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158–68. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources